ArticleCureus2025
Paradoxical Reaction With Intercostal Lymphadenopathy in Tuberculous Pleurisy.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paradoxical reaction (PR) is defined as the clinical or imaging worsening of tuberculosis lesions or the emergence of new lesions after anti-tuberculosis therapy. Although additional treatments, including corticosteroids, may be considered in severe cases, the mainstay management of a PR is close monitoring, as the condition is generally self-limited. Radiographic presentations are diverse, and currently, no specific radiographic features of this condition have been identified, which may lead to misdiagnosis as treatment failure, drug-resistant tuberculosis, or another infection. PRs in tuberculous pleurisy, once considered rare, typically manifest as increased pleural effusion or progression of infiltration. We present a rare case of tuberculous pleurisy in which intercostal lymphadenopathy enlargement occurred as a PR on the 22nd day of anti-tuberculosis therapy. The symptoms did not significantly affect the patient's quality of life, physical activity, or respiratory function, and the patient was closely monitored without modifying treatment or adding corticosteroids, showing improvement on the 34th day of anti-tuberculosis therapy. Two years have passed after the completion of treatment, and no recurrence of tuberculosis or PR has been observed. This case highlights the importance of clinician vigilance for PRs in tuberculosis management. During treatment for tuberculous pleurisy, unexplained intercostal lymphadenopathy should raise suspicion of a PR, and close monitoring without invasive tests or treatments is recommended.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.